<iframe src="//www.googletagmanager.com/ns.html?id=GTM-K799DP4&l=dataLayer" height="0" width="0" style="display:none;visibility:hidden"></iframe>
NAS:PODD (USA) Also Trade In: Germany

Insulet Corp $ 153.74 -2.74 (-1.75%)

Volume:
694,086
Avg Vol (1m):
1,089,849
Market Cap $:
9.44 Bil
Enterprise Value $:
9.74 Bil
P/E (TTM):
549.07
P/B:
37.85
Warning! GuruFocus has detected 2 Severe warning signs with PODD. Click here to check it out.
5D 3M YTD 1Y 5Y 10Y All 1Y (-%)
PE Ratio P/S Ratio P/B Ratio Price-FCF Ratio Market Cap
Current and historical daily P/E ratio for PODD (Insuletrp) from 2007 to Oct 21 2019. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. Insulet stock (PODD) PE ratio as of Oct 21 2019 is 549.07. More Details

Insulet PE Ratio (TTM) Chart

EMBED

Insulet PE Ratio (TTM) Historical Data

Total 1251
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Insulet PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2019-10-21549.1 2019-08-19544.8
2019-10-18549.1 2019-08-16536.6
2019-10-17558.9 2019-08-15540.8
2019-10-16555.8 2019-08-14522.8
2019-10-15555.1 2019-08-13545.6
2019-10-14543.8 2019-08-12539.5
2019-10-11547.8 2019-08-09544.0
2019-10-10553.2 2019-08-08520.7
2019-10-09552.6 2019-08-07508.4
2019-10-08546.7 2019-08-06511.2
2019-10-07564.5 2019-08-05421.2
2019-10-04555.7 2019-08-02431.8
2019-10-03566.8 2019-08-01437.7
2019-10-02561.8 2019-07-31439.1
2019-10-01581.5 2019-07-30449.4
2019-09-30589.0 2019-07-29446.8
2019-09-27585.2 2019-07-26442.8
2019-09-26589.6 2019-07-25440.5
2019-09-25591.3 2019-07-24441.3
2019-09-24587.6 2019-07-23434.8
2019-09-23566.1 2019-07-22431.7
2019-09-20556.4 2019-07-19432.8
2019-09-19545.0 2019-07-18436.9
2019-09-18528.7 2019-07-17433.0
2019-09-17518.1 2019-07-16427.4
2019-09-16511.1 2019-07-15431.1
2019-09-13511.6 2019-07-12429.5
2019-09-12516.1 2019-07-11442.1
2019-09-11518.5 2019-07-10435.4
2019-09-10522.8 2019-07-09424.8
2019-09-09526.4 2019-07-08419.1
2019-09-06560.8 2019-07-05428.0
2019-09-05567.3 2019-07-04427.1
2019-09-04561.1 2019-07-03427.1
2019-09-03599.8 2019-07-02425.4
2019-09-02550.6 2019-07-01423.2
2019-08-30550.6 2019-06-28426.4
2019-08-29544.7 2019-06-27507.0
2019-08-28536.9 2019-06-26501.3
2019-08-27540.9 2019-06-25504.6
2019-08-26551.3 2019-06-24511.8
2019-08-23550.3 2019-06-21520.7
2019-08-22554.3 2019-06-20519.8
2019-08-21549.9 2019-06-19524.9
2019-08-20544.4 2019-06-18515.7

Insulet PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Industry Medical Devices » Medical Devices NAICS : 339112 NAICS : 3841
Traded in other countries GOV.Germany PODD.USA
Address 100 Nagog Park, Acton, MA, USA, 01720
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and a wireless personal diabetes manager that controls the dosage and has an integrated blood glucose meter. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, more than 20,000 insulin-dependent diabetics in the United States have begun using it.